How will the 2028 IRA pricing changes for new drugs like Trulicity and Rexulti affect the company, and have PBM arrangements addressed future IRA changes?

The company will experience revenue decline from price reductions, but the 2027 tranche (affecting 2028) is estimated to be about 40% of the 2026 tranche's impact, implying a smaller revenue effect. Management is comfortable they have mitigated the margin impact. “We will suffer the revenue decline associated with the price reduction, but this next tranche represents about 40%. Am I right, David, about 40% of the 2026 tranche? So the impact -- revenue impact is going to be less in '27 than it was in '26. On the EBITDA side, yes, we are comfortable that we've mitigated the margin impact.”

Clarification on the 40% impact for the 2027 tranche compared to the previously stated 50%, and what operational/contracting improvements drove this.

The revenue impact for the 2027 tranche is still an estimate based on relative volume, as specific drugs are not yet definitively analyzed. The 40% is a guesstimate, not based on specific operational improvements since last quarter. “Raj, the revenue impact is yet to be definitively analyzed because we don't yet have the specific drug. So we're just guesstimating at this point based on the relative volume of the '27 tranche relative to the '26 tranche.”

What are the milestones and long-term outcomes for clinical capabilities like the falls risk program, especially in engaging payers and PBMs?

The company has an ongoing intensive education process with payers to highlight their value. The falls risk program is showing meaningful reductions in fall-related risk metrics in early, small-sample data, and more details will be provided as it rolls out and more representative data becomes available. “Our sample size is relatively small, but we've seen meaningful reductions in the fall-related risk metrics. And we'll be providing more detail as we continue to roll out this plan and we have more representative data to talk about.”

GRDN

Guardian Pharmacy Services (GRDN) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 6, 2026

Source: earnings call transcript

Executive summary

Guardian Pharmacy Services Q2 FY26 — Strong EBITDA Growth Amid IRA Headwinds

Guardian Pharmacy Services delivered a solid second quarter, demonstrating strong underlying business growth and effective mitigation of IRA pricing impacts on profitability. The company raised its full-year guidance for both revenue and adjusted EBITDA, driven by operational efficiencies and strategic expansions. Leadership transitions were completed to support future growth, while capital deployment remains focused on M&A and greenfield opportunities, with an eye on potential Omnicare assets.

Highlights

Reported revenue grew 2% in Q2 FY26, with underlying growth (absent IRA impact) in low double digits.
Adjusted EBITDA grew 23% in H1 FY26 compared to H1 FY25, reaching $29.7 million in Q2 FY26, up 19% YoY.
Full-year 2026 revenue guidance raised to $1.43 billion to $1.45 billion (from $1.4 billion to $1.42 billion).
Full-year 2026 adjusted EBITDA guidance raised to $129 million to $131 million (from $123 million to $127 million).
Cash balance increased to nearly $90 million at quarter end, up from approximately $65 million in the prior quarter.

Concerns

IRA pricing reductions negatively impacted reported revenue growth, which would have been low double digits without it.
Reported revenue is expected to decline by a low single-digit percentage in H2 FY26 due to continued IRA impact.
Recent acquisitions and greenfield startups continued to dilute consolidated adjusted EBITDA margin by approximately 60 basis points in Q2.
Higher fuel costs continued to pressure gross profit in Q2 FY26.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Revenue	$1.43 billion to $1.45 billion high materiality	FY26	High
Full-year 2026 Adjusted EBITDA	$129 million to $131 million high materiality	FY26	High
Underlying Revenue Growth (ex-IRA)	high single digits medium materiality	H2 FY26	Medium
Reported Revenue Growth	decline year-over-year by a low single-digit percentage medium materiality	H2 FY26	Medium
Adjusted EBITDA Margin	remain relatively stable medium materiality	Q3 FY26	Medium
Adjusted EBITDA Margin	typical seasonal increase medium materiality	Q4 FY26	Medium

Deals & partnerships

Wellness Concepts Acquisition of a long-term care pharmacy based in the Shenandoah Valley of Virginia.

Adds a service-oriented team with a strong reputation for quality; smaller in size but in line with desired pharmacy type.

Lexington, Kentucky Launch of a new greenfield pharmacy.

Marks Guardian's first location in Kentucky; collaborative effort between Tennessee and Cincinnati pharmacies; led by David Brown.

Risks & headwinds

IRA pricing reductions H2 FY26

Expected low single-digit percentage decline in H2 FY26 reported revenue

Mitigation:Disciplined execution across the business; successful mitigation of profitability impact; PBM arrangements.

Higher fuel costs Q2 FY26

Pressured gross profit in Q2 FY26

Mitigation:Implied by overall profitability management, but not explicitly stated.

Dilution from recent acquisitions and greenfield startups Q2 FY26

Reduced consolidated adjusted EBITDA margin by approximately 60 basis points in Q2 FY26

Mitigation:Continued progress in bringing these locations closer to consolidated margin.

Uncertainty around Omnicare assets Ongoing

Potential M&A opportunity, but deal not closed

Mitigation:Maintaining financial flexibility ('dry powder') and standing by in case of divestiture opportunities.

What to watch in Q3 FY26

Omnicare asset divestiture

Next quarter

Current Deal not closed, company standing by

Target Clarity on divestiture process or opportunity

Why it matters

Could represent a significant M&A opportunity for Guardian, impacting capital deployment strategy.

Also, at this point, we want to maintain dry powder until we know for certain what happens with the Omnicare assets in case there's any opportunity there.

Find out whether GRDN delivers this. Inve re-checks your case every morning.

Q&A highlights

How long do new acquisitions/greenfields take to reach corporate average profitability, and what is the pipeline for future M&A/greenfields?

New locations typically take about 4 years to reach corporate average profitability. The company has a very robust pipeline for both greenfields and M&A activity.

“We've always said that it takes us roughly 4 years to bring these new locations up to the corporate average profitability, some quicker, some may be a little longer depending on what has to be done.”

asked by Brian Tanquilut · answered by Fred Burke

2 min read 7 chapters

Detailed narrative

IRA Impact and Mitigation

Guardian Pharmacy Services successfully navigated the impact of IRA pricing reductions, which otherwise would have shown low double-digit revenue growth. Despite reported revenue pressure, adjusted EBITDA grew significantly due to disciplined execution and improved profitability. Management estimates the revenue impact from the next tranche of IRA changes in 2028 to be less severe than the 2026 tranche, representing about 40% of the 2026 impact.

Leadership Transitions

Fred Burke announced key leadership changes, with David Morris transitioning from CFO to COO and Will Mudd appointed as the new CFO. These internal promotions highlight the company's talent depth and succession planning, aiming to strengthen operational execution and financial discipline for future growth. Kendall Forbes, a co-founder, also retired, with gratitude expressed for his contributions.

Operational Excellence and Clinical Initiatives

David Morris highlighted the company's clinical capabilities, serving over 300,000 residents and completing over 50,000 clinical interventions in the first half of 2026. The falls risk program is expanding, showing meaningful improvement in early data. These initiatives aim to reduce medication-related risks and prevent adverse health outcomes, strengthening the value proposition for facility partners and engaging payers.

M&A and Greenfield Expansion Strategy

Guardian continues to pursue M&A and greenfield start-ups as key capital deployment strategies. Subsequent to quarter end, the company acquired Wellness Concepts in Virginia and launched a new greenfield pharmacy in Lexington, Kentucky. These expansions are consistent with their strategy of geographic growth and leveraging local market expertise, with new locations typically reaching corporate average profitability in about four years.

Regional Leadership Structure

A new regional leadership structure has been implemented, appointing eight Senior Vice Presidents from within the company. These experienced operators will provide guidance and assistance to local pharmacies, foster best practice sharing, and strengthen communication between pharmacies and the support organization. The objective is to bring greater consistency and accountability while preserving entrepreneurial culture and local decision-making.

Class B to Class A Stock Conversion

The final tranche of Class B common stock, approximately 13.5 million shares, is expected to convert to Class A common stock in late September. Management and directors holding a substantial majority of these shares are committed to a measured approach to liquidity to ensure an orderly process with minimal market disruption, with a trading restriction until early to mid-November.

Cash Position and Capital Deployment

The company ended the quarter with nearly $90 million in cash, up from $65 million, reflecting normalized cash conversion. While M&A and greenfield remain the primary focus for capital deployment, the company is maintaining 'dry powder' to remain flexible for potential opportunities, such as the Omnicare assets, and is exploring all options for capital allocation.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.